摘要
目的:探讨拓扑异构酶Ⅱα(TopoⅡα)和DNA依赖蛋白激酶催化亚单位(DNA-PKcs)在急性白血病(AL)患者中的表达及其与多药耐药的关系。方法:采用免疫组织化学SP法检测62例AL患者骨髓白血病细胞TopoⅡα和DNA-PKcs的表达。结果:1)TopoⅡα在耐药组和敏感组中阳性表达率分别为33.3%和69.0%,耐药组TopoⅡα阳性表达率明显低于敏感组(P<0.01)。2)DNA-PKcs在耐药组和敏感组中的阳性表达率分别为51.5%和20.7%,耐药组DNA-PKcs阳性表达率明显高于敏感组(P<0.05)。3)在TopoⅡα阳性表达的患者中,DNA-PKcs阳性表达组耐药率(61.5%)明显高于DNA-PKcs阴性表达组(16.7%)(P<0.05)。在DNA-PKcs阴性表达的患者中,TopoⅡα阴性表达组耐药率(61.9%)明显高于TopoⅡα阳性表达组(16.7%)(P<0.01)。TopoⅡα阳性表达DNA-PKcs阴性表达组耐药率最低(16.7%),而TopoⅡα阴性表达DNA-PKcs阳性表达组耐药率最高(90.0%)(P<0.001)。TopoⅡα和DNA-PKcs两者表达之间无相关性。结论:AL患者TopoⅡα表达水平下降,DNA-PKcs表达水平升高与临床耐药密切相关,联合检测TopoⅡα和DNA-PKcs对临床耐药和预后的判断有一定价值。
Objective: To investigate the expression of Topoisomerase IIalpha (TopoⅡα) and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) in acute leukemia (AL) patients and their correlation with clinical multidrug resistance. Methods: The expression of TopoⅡα and DNA-PKcs were measured in bone marrow mononuclear cells of 62 AL patients by SP immunohistochemistry method Results: 1)The positive expression rate of TopoⅡα in the treatment resistant group(33.3%)was significantly lower than that in the sensitive group(69.0%)(P<0.01). 2) The positive expression rate of DNA-PKcs in the treatment resistant group(51.5%)was significantly higher than that in the sensitive group(20.7%)(P<0.05). 3) In the positive expression cases of TopoⅡα, the multidrug resistance rate in the DNA-PKcs positive expression group (61.5%) was significantly higher than that in DNA-PKcs negative expression group (16.7%) (P<0.05). In the negative expression cases of DNA-PKcs, the multidrug resistance rate in the TopoⅡαnegative expression group (61.9%) was significantly higher than that in TopoⅡα positive expression group (16.7%) (P<0.01). The lowest multidrug resistance rate was in the group of TopoⅡα positive expression and DNA-PKcs negative expression (16.7%), the highest multidrug resistance rate was in the group of TopoⅡα negative expression and DNA-PKcs positive expression (90.0%) (P<0.001). There was no correlation between TopoⅡα and DNA-PKcs expression. Conclusions: The lower expression of TopoⅡαand the higher expression of DNA-PKcs have close relation with clinical multidrug resistance. The measurement of both TopoⅡαand DNA-PKcs expression would predict drug resistance and prognosis for AL patients.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2004年第22期1268-1271,共4页
Chinese Journal of Clinical Oncology
基金
辽宁省自然科学基金(编号:962303)
辽宁省教育基金资助(编号:20122152)
